title: Refining the treatment parameters of diabetic retinopathy: new prospects and limitations on the horizon.
authors.affiliation: Center for Ophthalmology, Eberhard-Karl University Tuebingen, Tuebingen, Germany. Electronic address: focke.ziemssen@med.uni-tuebingen.de.
authors.forename: Focke
authors.initials: F
authors.lastname: Ziemssen
authors.affiliation: Institute of Ophthalmology, St Franziskus Hospital, Muenster, Germany.
authors.forename: Georg
authors.initials: G
authors.lastname: Spital
mesh_terms: D020533:Angiogenesis Inhibitors / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized / Q000627:therapeutic use*; D000068258:Bevacizumab; D001786:Blood Glucose / Q000378:metabolism*; D003930:Diabetic Retinopathy / Q000188:drug therapy* / Q000378:metabolism*; D005260:Female; D006801:Humans; D008269:Macular Edema / Q000188:drug therapy*; D008297:Male; D042461:Vascular Endothelial Growth Factor A / Q000037:antagonists & inhibitors*
chemical_list: D020533:Angiogenesis Inhibitors; D061067:Antibodies, Monoclonal, Humanized; D001786:Blood Glucose; D042461:Vascular Endothelial Growth Factor A; D000068258:Bevacizumab